Nektar Therapeutics (NKTR)
1.36
+0.12
(+9.68%)
USD |
NASDAQ |
Apr 22, 16:00
1.365
0.00 (0.00%)
After-Hours: 20:00
Nektar Therapeutics Enterprise Value: -53.90M for April 22, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
April 22, 2024 | -53.90M |
April 19, 2024 | -75.93M |
April 18, 2024 | -61.24M |
April 17, 2024 | -55.73M |
April 16, 2024 | -30.03M |
April 15, 2024 | -15.34M |
April 12, 2024 | 3.026M |
April 11, 2024 | -13.50M |
April 10, 2024 | -66.75M |
April 09, 2024 | -74.09M |
April 08, 2024 | -63.08M |
April 05, 2024 | -61.24M |
April 04, 2024 | -61.24M |
April 03, 2024 | -112.65M |
April 02, 2024 | -129.18M |
April 01, 2024 | -137.61M |
March 28, 2024 | -132.08M |
March 27, 2024 | -141.10M |
March 26, 2024 | -138.36M |
March 25, 2024 | -140.54M |
March 22, 2024 | -135.88M |
March 21, 2024 | -138.86M |
March 20, 2024 | -138.36M |
March 19, 2024 | -144.20M |
March 18, 2024 | -147.54M |
Date | Value |
---|---|
March 15, 2024 | -145.67M |
March 14, 2024 | -145.70M |
March 13, 2024 | -147.54M |
March 12, 2024 | -140.20M |
March 11, 2024 | -150.90M |
March 08, 2024 | -136.69M |
March 07, 2024 | -128.15M |
March 06, 2024 | -136.54M |
March 05, 2024 | -141.28M |
March 04, 2024 | -138.36M |
March 01, 2024 | -160.39M |
February 29, 2024 | -173.25M |
February 28, 2024 | -171.41M |
February 27, 2024 | -165.90M |
February 26, 2024 | -175.39M |
February 23, 2024 | -173.02M |
February 22, 2024 | -177.11M |
February 21, 2024 | -171.56M |
February 20, 2024 | -176.61M |
February 16, 2024 | -167.37M |
February 15, 2024 | -161.99M |
February 14, 2024 | -156.25M |
February 13, 2024 | -178.26M |
February 12, 2024 | -167.35M |
February 09, 2024 | -167.73M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-384.62M
Minimum
Mar 30 2023
5.078B
Maximum
Jul 03 2019
1.388B
Average
1.701B
Median
Oct 23 2019
Enterprise Value Benchmarks
Stereotaxis Inc | 191.08M |
Vanda Pharmaceuticals Inc | -112.08M |
Cara Therapeutics Inc | -60.52M |
Marinus Pharmaceuticals Inc | 3.709M |
DiaMedica Therapeutics Inc | 42.38M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -42.08M |
Revenue (Quarterly) | 23.88M |
Total Expenses (Quarterly) | 54.54M |
EPS Diluted (Quarterly) | -0.22 |
Gross Profit Margin (Quarterly) | 69.51% |
Profit Margin (Quarterly) | -176.2% |
Earnings Yield | -107.4% |
Normalized Earnings Yield | -57.45 |